Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4

International Immunopharmacology

Volumn 9, Issue 13-14, 2009, Pages 1562-1567

  Takeuchi, Ario ^a   Kamiryou, Yoriyuki ^b   Yamada, Hisakata ^a   Eto, Masatoshi ^b   Shibata, Kensuke ^a   Haruna, Kennichi ^c   Naito, Seiji ^b   Yoshikai, Yasunobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c ROHTO Pharmaceutical Co Ltd   (Japan)

Author keywords

Biological response modifier; Cytokine; Cytotoxic activity; Toll like receptor; Tumor immunology

Indexed keywords

INTERLEUKIN 12P40; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; XANTHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG MECHANISM; MACROPHAGE ACTIVATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR GROWTH; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CYTOTOXICITY, IMMUNOLOGIC; INTERLEUKIN-12; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM TRANSPLANTATION; POLYSACCHARIDES, BACTERIAL; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350564316     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.09.012     Document Type: Article

References (34)

1. Storni T., Manolova V., Didierlaurent A., Sirard J.C., Röthlisberger P., Bachmann M.F., et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33 6 (2003) 1465-1470
2. Matsunaga K., Morita I., Oguchi Y., Fujii T., Yoshikumi C., and Nomoto K. The effect of a biological response modifier, PSK, on the intestinal immune system in tumor-bearing mice. Anticancer Res 7 3 Pt B (1987) 509-512
3. Kawai T., and Akira S. TLR signaling. Cell Death Differ 13 5 (2006) 816-825
4. Reisser D., Pance A., and Jeannin J.F. Mechanisms of the antitumoral effect of lipid A. Bioessays 24 3 (2002) 284-289
5. Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., and Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149 Suppl 66 (2003) 53-56
6. Jahrsdorfer B., Mühlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11 4 (2005) 1490-1499
7. Tsukagoshi S., Hashimoto Y., Fujii G., Kobayashi H., Nomoto K., and Orita K. Krestin (PSK). Cancer Treat Rev 11 2 (1984) 131-155
8. Sabolovic D., and Galoppin L. Effect of a protein bound polysaccharide (PS-K) on tumor development and infections in splenectomized rats and mice. Int J Immunopharmacol 8 1 (1986) 41-46
9. Suda M., Ohno N., Adachi Y., and Yadomae T. Relationship between the tissue distribution and antitumor activity of highly branched (1---->3)-beta-d-glucan, SSG. Biol Pharm Bull 17 1 (1994) 131-135
10. Ebina T., and Fujimiya Y. Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biotherapy 11 4 (1998) 259-265
11. Ohno N., Miura N.N., Nakajima M., and Yadomae T. Antitumor 1, 3-beta-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull 23 7 (2000) 866-872
12. Kamiryo Y., Yajima T., Saito K., Nishimura H., Fushimi T., Ohshima Y., et al. Soluble branched (1, 4)-beta-d-glucans from Acetobacter species enhance antitumor activities against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 115 5 (2005) 769-776
13. Saito K., Yajima T., Nishimura H., Aiba K., Ishimitsu R., Matsuguchi T., et al. Soluble branched beta-(1, 4)glucans from Acetobacter species show strong activities to induce interleukin-12 in vitro and inhibit T-helper 2 cellular response with immunoglobulin E production in vivo. J Biol Chem 278 40 (2003) 38571-38578
14. Jansson P.E., Kenne L., and Lindberg B. Structure of extracellular polysaccharide from Xanthomonas campestris. Carbohydr Res 45 (1975) 275-282
15. Cadmus M.C., Rogovin S.P., Burton K.A., Pittsley J.E., Knutson C.A., and Jeanes A. Colonial variation in Xanthomonas campestris NRRL B-1459 and characterization of the polysaccharide from a variant strain. Can J Microbiol 22 7 (1976) 942-948
16. Becker A., Katzen F., Puhler A., and Ielpi L. Xanthan gum biosynthesis and application: a biochemical/genetic perspective. Appl Microbiol Biotechnol 50 2 (1998) 145-152
17. Sutherland I.W. Novel and established applications of microbial polysaccharides. Trends Biotechnol 16 1 (1998) 41-46
18. Stankowski J.D., Mueller B.E., and Zeller S.G. Location of a second O-acetyl group in xanthan gum by the reductive-cleavage method. Carbohydr Res 241 (1993) 321-326
19. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 97 25 (2000) 13766-13771
20. Bulut Y., Faure E., Thomas L., Equils O., and Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 167 2 (2001) 987-994
21. Nanba H., and Kuroda H. Antitumor mechanisms of orally administered shiitake fruit bodies. Chem Pharm Bull (Tokyo) 35 6 (1987) 2459-2464
22. Harada M., Matsunaga K., Oguchi Y., Iijima H., Tamada K., Abe K., et al. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 70 3 (1997) 362-372
23. Schatzkin A., Lanza E., Corle D., Lance P., Iber F., Caan B., et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342 16 (2000) 1149-1155
24. Cheung N.K., Modak S., Vickers A., and Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51 10 (2002) 557-564
25. Cheung N.K., and Modak S. Oral (1---->3),(1---->4)-beta-d-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8 5 (2002) 1217-1223
26. Ishizaka S., Sugawara I., Hasuma T., Morisawa S., and Moller G. Immune responses to xanthan gum. I. The characteristics of lymphocyte activation by xanthan gum. Eur J Immunol 13 3 (1983) 225-231
27. Seya T., Matsumoto M., Tsuji S., Begum N.A., Azuma I., and Toyoshima K. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect 4 9 (2002) 955-961
28. Okamoto M., Oshikawa T., Tano T., Ahmed S.U., Kan S., Sasai A., et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29 1 (2006) 78-86
29. D'Agostini C., Pica F., Febbraro G., Grelli S., Chiavaroli C., and Garaci E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 5 7-8 (2005) 1205-1212
30. McDermott M.F. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 47 4 (2001) 619-635
31. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
32. Warger T., Osterloh P., Rechtsteiner G., Fassbende M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108 2 (2006) 544-550
33. Ballas Z.K., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 5 (1996) 1840-1845
34. Slifka M.K., Pagarigan R.R., and Whitton J.L. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol 164 4 (2000) 2009-2015